{
    "title": "108_hr4899",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Sustainable Drug Pricing Act''.\n\nSEC. 2. AGREEMENTS REGARDING PRICES OF BRAND-NAME PRESCRIPTION DRUGS; \n              RELATION TO CERTAIN TAX DEDUCTIONS AND CREDITS.\n\n    Part D of title III of the Public Health Service Act (42 U.S.C. \n254b et seq.) is amended by adding at the end the following subpart:\n\n                 ``Subpart XI--Sustainable Drug Pricing\n\n``SEC. 340H. AGREEMENTS REGARDING PRICES OF BRAND-NAME PRESCRIPTION \n              DRUGS; RELATION TO CERTAIN TAX DEDUCTIONS AND CREDITS.\n\n    ``(a) In General.--\n            ``(1) Agreement.--The Secretary may in accordance with this \n        section enter into an agreement with any manufacturer of a \n        brand-name prescription drug for purposes of--\n                    ``(A) section 280I of the Internal Revenue Code of \n                1986 (relating to the allowance of a deduction for \n                expenditures relating to the advertising, promoting, or \n                marketing of such drug); and\n                    ``(B) section 901(l) of such Code (relating to the \n                allowance of a foreign tax credit for income, war \n                profits, or excess profits taxes paid or accrued with \n                respect to such drug).\n            ``(2) Coordination with tax provisions.--For purposes of \n        the provisions of the Internal Revenue Code of 1986 referred to \n        in paragraph (1), an agreement under this section shall be \n        considered to be in effect with respect to a brand-name \n        prescription drug unless the Secretary transmits to the \n        Secretary of the Treasury a notice in writing that such an \n        agreement is not in effect.\n            ``(3) Negotiations.--The Secretary shall negotiate with any \n        manufacturer of a brand-name prescription drug that in good \n        faith seeks an agreement under paragraph (1), and shall make \n        reasonable efforts to enter into such an agreement with the \n        manufacturer.\n    ``(b) Public Health Objectives of Agreement.--The purpose of an \nagreement under subsection (a) regarding a drug is to establish the \nmaximum price at which the drug may be sold at wholesale under the \nagreement, reasonably taking into account--\n            ``(1) the affordability of the drug in relation to the \n        public-health need for the drug; and\n            ``(2) the need for the manufacturer to invest in research \n        and development activities toward the development of new drugs \n        that will benefit the public health.\n    ``(c) Duration of Agreement; Renegotiation.--\n            ``(1) In general.--With respect to taxable years of a \n        manufacturer, the Secretary may enter into an agreement under \n        subsection (a) regarding a drug only if the agreement contains \n        provisions in accordance with the following:\n                    ``(A) In the case of the agreement as first in \n                effect, the agreement will be in effect for not fewer \n                than four successive taxable years.\n                    ``(B) In the case of taxable years following such \n                four taxable years, the agreement may be periodically \n                renegotiated at the initiative of the manufacturer or \n                the Secretary, except that any agreement that takes \n                effect pursuant to such a renegotiation will remain in \n                effect for not fewer than four taxable years.\n                    ``(C) Each agreement will apply to the entirety of \n                the taxable years with which the agreement is \n                concerned, except that in the case of the taxable year \n                during which the drug first enters the commercial \n                market, the applicability of the agreement will begin \n                on the date during the taxable year on which commercial \n                marketing of the drug begins.\n            ``(2) Variation in maximum price under agreement.--With \n        respect to the maximum price established for a drug under an \n        agreement under subsection (a), this section may not be \n        construed as requiring that the agreement provide that a single \n        maximum price be in effect throughout the taxable years with \n        which the agreement is concerned. The maximum price may vary \n        under the agreement according to the terms of the agreement.\n    ``(d) Violation of Agreement; Liquidated Penalty.--\n            ``(1) In general.--The Secretary may enter into an \n        agreement under subsection (a) regarding a drug only if--\n                    ``(A) the agreement specifies the amount that, as a \n                liquidated penalty, the Secretary may require the \n                manufacturer involved to pay to the United States for \n                failing to maintain substantial compliance with the \n                agreement; and\n                    ``(B) such amount is sufficient to deter violations \n                of the agreement.\n            ``(2) Hearing; loss of effective status of agreement.--\n                    ``(A) Hearing.--If, after providing notice and an \n                opportunity for a hearing, the Secretary determines \n                that a manufacturer has failed to maintain substantial \n                compliance with the agreement under subsection (a), the \n                Secretary shall order the manufacturer--\n                            ``(i) to pay to the United States an amount \n                        as a penalty for such failure, which amount \n                        does not exceed the amount specified under \n                        paragraph (1)(A) as a liquidated penalty; and\n                            ``(ii) to take appropriate action to bring \n                        the manufacturer into compliance with the \n                        agreement.\n                    ``(B) Loss of effective status.--If a manufacturer \n                fails to comply with an order under subparagraph (A), \n                the Secretary may transmit to the Secretary of the \n                Treasury a notice in writing that an agreement under \n                this section is not in effect with respect to the \n                brand-name prescription drug involved.\n    ``(e) General Provisions.--\n            ``(1) Individual drug agreements.--The Secretary shall \n        ensure that each agreement under subsection (a) concerns only \n        one brand-name prescription drug.\n            ``(2) Monitoring of compliance.--With respect to brand-name \n        prescription drugs for which agreements under subsection (a) \n        are in effect, the Secretary shall monitor the prices at which \n        such drugs are being sold and determine whether the \n        manufacturers involved are in compliance with the agreements. \n        The Secretary may require, as a condition of a entering into an \n        agreement under subsection (a) with a manufacturer, that the \n        agreement include provisions regarding the cooperation of the \n        manufacturer with such monitoring of prices.\n            ``(3) Access to records.--The Secretary may require, as a \n        condition of a entering into an agreement under subsection (a) \n        with a manufacturer, that the manufacturer provide the \n        Secretary, during negotiations and after the agreement is made, \n        with access to financial records of the manufacturer that \n        relate to the brand-name prescription drug involved.\n            ``(4) Consideration of compliance record.--In determining \n        to what extent to establish requirements under paragraphs (2) \n        and (3) with respect to an agreement under subsection (a) with \n        a manufacturer, the Secretary shall take into account whether \n        the manufacturer has maintained substantial compliance with any \n        other agreements under such subsection that have been made by \n        the manufacturer.\n    ``(f) Advisory Panel on Drug-Price Negotiations.--\n            ``(1) In general.--The Secretary shall establish an \n        advisory panel to be known as the Advisory Panel on Drug-Price \n        Negotiations (in this subsection referred to as the `Advisory \n        Panel').\n            ``(2) Duties.--The Advisory Panel shall provide advice to \n        the Secretary on establishing prices for the sale of brand-name \n        prescription drugs at wholesale under agreements under \n        subsection (a). Not later than one year after the date on which \n        the initial appointments to the Advisory Panel under paragraph \n        (3) are completed, the Panel shall--\n                    ``(A) select, from brand-name prescription drugs in \n                commercial distribution as of the date of the enactment \n                of the Sustainable Drug Pricing Act--\n                            ``(i) a list of 25 drugs that the Panel \n                        considers important to the public health; and\n                            ``(ii) a list of the 25 most commonly \n                        prescribed drugs in the United States, \n                        exclusive of drugs included on the list under \n                        clause (i); and\n                    ``(B) submit to the Secretary the recommendations \n                of the Panel with respect to such prices for drugs on \n                the lists.\n            ``(3) Composition.--The Advisory Panel shall be composed of \n        five members appointed by the Secretary from among individuals \n        who are not officers or employees of the Federal Government. Of \n        such members--\n                    ``(A) one shall be a representative of the \n                pharmaceutical industry;\n                    ``(B) one shall be a representative of retail \n                consumers generally;\n                    ``(C) one shall be a representative of retail \n                consumers who are members of racial or ethnic minority \n                groups;\n                    ``(D) one shall be an academic with expertise in \n                health care economics; and\n                    ``(E) one shall be an academic with expertise in \n                public health.\n        The Secretary shall appoint the initial members of the Advisory \n        Panel not later than 180 days after the date of the enactment \n        of the Sustainable Drug Pricing Act.\n            ``(4) Chair.--The Advisory Panel shall select, by recorded \n        vote, a member of the Panel to serve as the chair of the Panel.\n            ``(5) Terms.--\n                    ``(A) In general.--Each member of the Advisory \n                Panel shall be appointed for a term of four years, \n                except that the term of each of the initial members \n                expires December 31, 2007.\n                    ``(B) Service after expiration of term.--A member \n                of the Advisory Panel may continue to serve after the \n                expiration of the term of the member until a successor \n                is appointed.\n            ``(6) Vacancies.--\n                    ``(A) Authority of advisory panel.--A vacancy in \n                the membership of the Advisory Panel does not affect \n                the power of the remaining members to carry out the \n                duties of the Panel.\n                    ``(B) Appointment of successors.--A vacancy in the \n                membership of the Advisory Panel shall be filled in the \n                manner in which the original appointment was made.\n                    ``(C) Incomplete term.--If a member of the Advisory \n                Panel does not serve the full term under paragraph \n                (5)(A), the Secretary, not later than 30 days after the \n                date on which the vacancy occurs, shall appoint an \n                individual to serve as a member of the Advisory Panel \n                for the remainder of such term.\n    ``(g) Definitions.--For purposes of this section:\n            ``(1) The term `brand-name prescription drug' means a drug \n        meeting each of the following criteria:\n                    ``(A) An approved application under section \n                505(b)(1) of the Federal Food, Drug, and Cosmetic Act \n                is in effect for the drug, or in the case of a drug \n                that is a biological product, a biologics license is in \n                effect for the drug under section 351 of this Act.\n                    ``(B) The drug is subject to section 503(b)(1) of \n                the Federal Food, Drug, and Cosmetic Act.\n                    ``(C) A period of market exclusivity is in effect \n                with respect to the drug pursuant to a patent or \n                pursuant to section 505(j) or 505A of such Act.\n            ``(2) The term `drug' has the meaning given such term in \n        section 201(g)(1) of such Act.''.\n\nSEC. 3. DENIAL OF CERTAIN TAX BENEFITS UNLESS UNLESS PRICING AGREEMENT \n              FOR BRAND-NAME PRESCRIPTION DRUGS IS IN EFFECT.\n\n    (a) Deductions for Advertising.--\n            (1) In general.--Part IX of subchapter B of chapter 1 of \n        subtitle A of the Internal Revenue Code of 1986 (relating to \n        items not deductible) is amended by adding at the end the \n        following:\n\n``SEC. 280I. DENIAL OF DEDUCTIONS FOR ADVERTISING FOR BRAND-NAME \n              PRESCRIPTION DRUGS UNLESS PRICING AGREEMENT IS IN EFFECT.\n\n    ``(a) In General.--No deduction shall be allowed under this chapter \nfor any taxable year for any expenditure relating to the advertising, \npromoting, or marketing (in any medium) of any brand-name prescription \ndrug manufactured by the taxpayer.\n    ``(b) Exception for Qualified Pricing Agreement.--\n            ``(1) In general.--Subsection (a) shall not apply with \n        respect to any brand-name prescription drug for a taxable year \n        if there is in effect for the entire taxable year a qualified \n        pricing agreement with respect to such drug.\n            ``(2) Special rule regarding initial commercial \n        marketing.--In the case of the taxable year during which a \n        brand-name prescription drug first enters the commercial \n        market, subsection (a) shall not apply with respect to such \n        drug for such taxable year if a qualified pricing agreement \n        with respect to the drug is in effect on the date of such entry \n        and remains in effect throughout the remainder of such year.\n    ``(c) Definitions.--For purposes of this section--\n            ``(1) Qualified pricing agreement.--The term `qualified \n        pricing agreement' means an agreement entered into under \n        section 340H of the Public Health Service Act.\n            ``(2) Brand-name prescription drug.--The term `brand-name \n        prescription drug' has the meaning given such term in section \n        340H of the Public Health Service Act.\n    ``(d) Aggregation Rules.--For purposes of this section, all members \nof the same controlled group of corporations (within the meaning of \nsection 52(a)) and all persons under common control (within the meaning \nof section 52(b)) shall be treated as 1 person.''.\n            (2) Clerical amendment.--The table of sections for such \n        part IX is amended by adding after the item relating to section \n        280H the following:\n\n``280I. Denial of deductions for advertising for brand-name \n                            prescription drugs unless pricing agreement \n                            is in effect.''.\n    (b) Foreign Tax Credit.--Section 901 of such Code (relating to \ntaxes of foreign countries and of possessions of United States) is \namended by redesignating subsection (l) as subsection (m) and by \ninserting after subsection (k) the following new subsection:\n    ``(l) Denial of Foreign Tax Credit, Etc. With Respect to Brand-Name \nPrescription Drugs Unless Pricing Agreement Is in Effect.--\n            ``(1) In general.--Notwithstanding any other provision of \n        this part, no credit shall be allowed under subsection (a) for \n        any income, war profits, or excess profits taxes paid or \n        accrued (or deemed paid under section 902 or 960) with respect \n        to any brand-name prescription drug manufactured by the \n        taxpayer.\n            ``(2) Exception for qualified pricing agreement.----\n                    ``(A) In general.--Paragraph (1) shall not apply \n                with respect to any brand-name prescription drug for a \n                taxable year if there is in effect for the entire \n                taxable year a qualified pricing agreement with respect \n                to such drug.\n                    ``(B) Special rule regarding initial commercial \n                marketing.--In the case of the taxable year during \n                which a brand-name prescription drug first enters the \n                commercial market, paragraph (1) shall not apply with \n                respect to such drug for such taxable year if a \n                qualified pricing agreement with respect to the drug is \n                in effect on the date of such entry and remains in \n                effect throughout the remainder of such year.\n            ``(3) Definitions.--For purposes of this subsection, the \n        terms `qualified pricing agreement' and `brand-name \n        prescription drug' have the meanings given such terms by \n        section 280I.\n            ``(4) Aggregation rules.--For purposes of this subsection, \n        a rule similar to the rule of section 280I(d) shall apply. ''.\n    (c) Effective Date.--The amendments made by this section shall \napply to taxable years beginning after December 31, 2005.\n\nSEC. 4. FEDERAL REGISTER NOTICE.\n\n    Not later than 90 days after the date of the enactment of this Act, \nthe Secretary of Health and Human Services shall publish in the Federal \nRegister a notice that informs manufacturers of brand-name prescription \ndrugs of the provisions of the amendments made by this Act, and that \ninvites the manufacturers to enter into negotiations with the Secretary \nfor purposes of entering into agreements under section 340H of the \nPublic Health Service Act."
}